Ozempic/ Extensior (Abbott co-marketed) / Rybelsus (oral form)Innovator semaglutide for type 2 diabetes in India 2026
by Novo Nordisk · ₹5,660–9,100/month (Ozempic, post April 2026 price cut) · DCGI approved December 2025 (Ozempic injectable), 2022 (Rybelsus oral tablet), February 2026 (Extensior via Abbott)
| Active ingredient | Semaglutide (GLP-1 receptor agonist) |
| Indication | Type 2 Diabetes |
| Manufacturer | Novo Nordisk A/S |
| DCGI status | Approved December 2025 (Ozempic injectable), 2022 (Rybelsus oral tablet), February 2026 (Extensior via Abbott) |
| Price (MRP) | ₹5,660–9,100/month (Ozempic, post April 2026 price cut) Effective April 1, 2026, Novo Nordisk reduced Ozempic prices ~36% in response to Indian generic launches. The 0.25 mg starting dose is now ₹5,660/month (₹202/day). |
| Format | Prefilled FlexTouch pen (0.25 mg, 0.5 mg, 1 mg weekly) · Rybelsus oral tablet (3 mg, 7 mg, 14 mg daily) |
| Prescription | Schedule H — required |
How Ozempic compares
Ozempic is Novo Nordisk's original innovator brand of injectable semaglutide for type 2 diabetes — the first global launch and the molecule on which all Indian generics are based. Sister brands extend Ozempic's reach across distribution channels: Rybelsus is the oral tablet form (same molecule, daily dosing), and Extensior is the Abbott-co-marketed Ozempic brand launched February 2026 to deepen prescription-channel coverage through Abbott's diabetes-care field force. Ozempic carries the full SUSTAIN-6 cardiovascular outcomes evidence and remains the originator reference product, but pricing now sits well above Indian generics after Novo's April 2026 ~36% price cut.
About Novo Nordisk
Novo Nordisk invented semaglutide and held the Indian patent until expiry on March 20, 2026. The company's globally-recognised clinical trial programme — SUSTAIN-6 (CV outcomes in T2D), STEP (obesity), SELECT (CV outcomes without diabetes) — underpins the entire semaglutide market. Ozempic remains the originator brand with the deepest evidence base. The February 2026 Abbott × Novo Nordisk partnership launched Extensior as a second-brand variant of Ozempic, broadening access through Abbott's specialist endocrinology and diabetology distribution.
Who is Ozempic for?
Ozempic is approved in India for type 2 diabetes mellitus in adults. Typically used as add-on therapy when metformin + lifestyle aren't achieving glycaemic targets, or as first-line in T2D patients with established cardiovascular disease, obesity, or chronic kidney disease per RSSDI 2024 guidelines.
Not sure if you qualify? Take the 5-minute Indian-guideline eligibility check →
Ozempic for specific conditions
Ozempic cost in India
MRP for Ozempic: ₹5,660–9,100/month (Ozempic, post April 2026 price cut). Actual pharmacy pricing varies by city, pharmacy, and channel. Online prescription pharmacies typically offer modest discounts off MRP with cold-chain delivery; hospital pharmacy pricing is usually at MRP.
Full dose-by-dose pricing + hidden costs (consults, labs, needles): Ozempic price in India 2026 →
Compared to other GLP-1 brands in India
Ozempic is Novo Nordisk's innovator brand. Indian generic semaglutides (Sundae, Noveltreat, Obeda, Semaglyn, Sembolic, Samakind, and others) contain the same active molecule at ₹1,290–3,500/month — substantially cheaper than Ozempic's ₹5,660–9,100/month (Ozempic, post April 2026 price cut). For tirzepatide (a different molecule with stronger weight outcomes), see Mounjaro.
Ozempic — frequently asked questions
Is Ozempic available in India? Is it DCGI-approved?+
What does Ozempic cost in India in 2026?+
Do I need a prescription to buy Ozempic?+
Who is Ozempic for?+
How does Ozempic compare to Indian generic semaglutides?+
Where can I buy Ozempic in India?+
GLP-1 Check is informational, not a medical diagnosis. Semaglutide is a Schedule H drug in India and requires a prescription from a registered medical practitioner. Always consult a qualified physician before starting any treatment.